13-Nitro-N-[3-(trifluoromethyl)phenyl]-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-9-carboxamide

Catalog No. :
ACCAHE337
CAS No. :
866157-23-5
Molecular Formula :
C21H14F3N3O4
Molecular Weight :
429.35

IUPAC Name:2-nitro-N-(3-(trifluoromethyl)phenyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carboxamide

13-Nitro-N-[3-(trifluoromethyl)phenyl]-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-9-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$324.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name13-Nitro-N-[3-(trifluoromethyl)phenyl]-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-9-carboxamide
IUPAC Name2-nitro-N-(3-(trifluoromethyl)phenyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carboxamide
Molecular FormulaC21H14F3N3O4
Molecular Weight429.35
SMILESO=C(N1C2=CC=CC=C2OC3=CC=C([N+]([O-])=O)C=C3C1)NC4=CC=CC(C(F)(F)F)=C4
InChI KeyKIYDBJRTFHOVFI-UHFFFAOYSA-N
Synonym13-nitro-N-[3-(trifluoromethyl)phenyl]-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-9-carboxamide;Dibenz[b,f][1,4]oxazepine-10(11H)-carboxamide, 2-nitro-N-[3-(trifluoromethyl)phenyl]-
CAS No.866157-23-5

Synthetic Route by SureRoute

1. ACCAHE337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCAHE337 route product structure diagram
    ACCAHE337866157-23-5
Inquiry

2. ACCAHE337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRAUC529 route compound structure diagram
    ACRAUC5292646-97-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCAHE337 route product structure diagram
    ACCAHE337866157-23-5
Inquiry

Comments (0)